Showing results (151-160 of 198) with videos related to
Sort By:
Pageof 20
BMJ Open|December 22, 2021
Kyushu and Okinawa Population Study (KOPS): a large prospective cohort study in JapanHiroaki Ikezaki, Norihiro Furusyo, Ryoko Nakashima, et al.Journal of Hepatology|August 15, 2012
Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trialNorihiro Furusyo, Eiichi Ogawa, Masayuki Sudoh, et al.World Journal of Hepatology|November 27, 2015
Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis CSatoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, et al.Surgical Case Reports|March 15, 2017
Successful surgical intervention for rectal perforation due to polyarteritis nodosa: report of a caseKeiji Yoshiya, Yu Imamura, Yu Nakaji, et al.Journal of Gastroenterology|December 4, 2016
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1bEiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 18, 2005
Body surface area is an independent factor contributing to the effects of lamivudine treatmentMakoto Nakamuta, Kazuhiro Kotoh, Yuichi Tanabe, et al.Antiviral Research|October 10, 2018
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney diseaseEiichi Ogawa, Norihiro Furusyo, Koichi Azuma, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 21, 2015
Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis CHiroaki Ikezaki, Hideyuki Nomura, Norihiro Furusyo, et al.World Journal of Gastroenterology|February 21, 2006
Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease StudyNorihiro Furusyo, Hiroaki Takeoka, Kazuhiro Toyoda, et al.BMJ Open|June 22, 2019
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in JapanAtaru Igarashi, Norihiro Furusyo, Eiichi Ogawa, et al.Pageof 20